Clinical trial
An Open-Label Evaluation of the Independent Effects of Coadministration of a…
NCT00399295 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00399295 |
|---|---|
| Title | An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg |
| Official title | An Open-Label Evaluation of the Independent Effect of Coadministration of a High Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCL) 16 mg |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Analgesia |
| Intervention type | Drug |
| Interventions | Hydromorphone HCL 16mg, Dilaudid SR 16mg, Naltrexone (opioid antagonist) 50mg. |
| Enrollment | 30 |
| Completion | Jun 1, 1997 |
| First posted | Nov 14, 2006 |
| Last update posted | Apr 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: